State Street Corp decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.9% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 41,974,017 shares of the company’s stock after selling 389,918 shares during the quarter. State Street Corp owned about 3.98% of Eli Lilly and worth $3,454,470,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after acquiring an additional 1,610,885 shares during the last quarter. BlackRock Inc. increased its stake in Eli Lilly and by 2.1% during the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after acquiring an additional 1,323,259 shares during the last quarter. Janus Henderson Group PLC increased its stake in Eli Lilly and by 7,093.5% during the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after acquiring an additional 9,223,251 shares during the last quarter. Geode Capital Management LLC increased its stake in Eli Lilly and by 8.4% during the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after acquiring an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC increased its stake in Eli Lilly and by 2.8% during the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after acquiring an additional 237,619 shares during the last quarter. Hedge funds and other institutional investors own 76.61% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/11/23/state-street-corp-has-3-45-billion-position-in-eli-lilly-and-company-lly.html.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold a total of 772,003 shares of company stock valued at $64,837,441 over the last ninety days. 0.20% of the stock is owned by company insiders.
Eli Lilly and Company (LLY) opened at $83.68 on Thursday. The stock has a market capitalization of $91,919.42, a price-to-earnings ratio of 20.41, a P/E/G ratio of 1.84 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $64.18 and a fifty-two week high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.88 EPS. research analysts anticipate that Eli Lilly and Company will post 4.21 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
LLY has been the subject of several recent analyst reports. Jefferies Group LLC reissued a “buy” rating and set a $89.00 target price on shares of Eli Lilly and in a research note on Monday, September 11th. BMO Capital Markets reissued an “underperform” rating and set a $71.00 target price (down previously from $73.00) on shares of Eli Lilly and in a research note on Wednesday, September 6th. Piper Jaffray Companies reissued an “overweight” rating and set a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a research note on Friday, September 8th. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their target price for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Finally, Berenberg Bank reissued a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research note on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $89.97.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.